This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. IN8bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0. IN8bio's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.
As of today (2025-04-01), IN8bio's share price is $0.1664. IN8bio's Median PS Value is $0.00. Therefore, IN8bio's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for IN8bio's Median PS Value or its related term are showing as below:
INAB's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.67 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
IN8bio Median PS Value Historical Data
The historical data trend for IN8bio's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IN8bio's Median PS Value
For the Biotechnology subindustry, IN8bio's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IN8bio's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IN8bio's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where IN8bio's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is .
IN8bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IN8bio (NAS:INAB) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
IN8bio's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.1664
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IN8bio Median PS Value Related Terms
Thank you for viewing the detailed overview of IN8bio's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INAB has been successfully added to your 